Abstract
The ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate such recurrences, remain major clinical challenges in oncology. While many potential molecular biomarkers have been identified and tested previously, none have greatly improved the accuracy of specimen evaluation over routine histopathological criteria and, to date, they predict individual outcomes poorly. The ongoing development of high-throughput proteomic profiling technologies is opening new avenues for the investigation of cancer and, through application in tissue-based studies and animal models, will facilitate the identification of molecular signatures that are associated with breast tumor cell phenotype. The appropriate use of these approaches has the potential to provide efficient biomarkers, and to improve our knowledge of tumor biology. This, in turn, will enable the development of targeted therapeutics aimed at ameliorating the lethal dissemination of breast cancer. In this review, we focus on the accumulating proteomic signatures of breast tumor progression, particularly those that correlate with the occurrence of distant metastases, and discuss some of the expected future developments in the field.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 457-467 |
| Number of pages | 11 |
| Journal | Expert Review of Proteomics |
| Volume | 5 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 1 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- 2D separation
- Biomarkers
- Breast cancer
- Laser-capture microdissection
- Molecular prognostics
- Oncoproteomics
- Tissue microarray
ASJC Scopus subject areas
- Biotechnology
- Genetics
- Molecular Biology
Cite this
Breast tumor metastasis : Analysis via proteomic profiling. / Goodison, Steven; Urquidi, Virginia.
In: Expert Review of Proteomics, Vol. 5, No. 3, 01.06.2008, p. 457-467.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Breast tumor metastasis
T2 - Analysis via proteomic profiling
AU - Goodison, Steven
AU - Urquidi, Virginia
PY - 2008/6/1
Y1 - 2008/6/1
N2 - The ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate such recurrences, remain major clinical challenges in oncology. While many potential molecular biomarkers have been identified and tested previously, none have greatly improved the accuracy of specimen evaluation over routine histopathological criteria and, to date, they predict individual outcomes poorly. The ongoing development of high-throughput proteomic profiling technologies is opening new avenues for the investigation of cancer and, through application in tissue-based studies and animal models, will facilitate the identification of molecular signatures that are associated with breast tumor cell phenotype. The appropriate use of these approaches has the potential to provide efficient biomarkers, and to improve our knowledge of tumor biology. This, in turn, will enable the development of targeted therapeutics aimed at ameliorating the lethal dissemination of breast cancer. In this review, we focus on the accumulating proteomic signatures of breast tumor progression, particularly those that correlate with the occurrence of distant metastases, and discuss some of the expected future developments in the field.
AB - The ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate such recurrences, remain major clinical challenges in oncology. While many potential molecular biomarkers have been identified and tested previously, none have greatly improved the accuracy of specimen evaluation over routine histopathological criteria and, to date, they predict individual outcomes poorly. The ongoing development of high-throughput proteomic profiling technologies is opening new avenues for the investigation of cancer and, through application in tissue-based studies and animal models, will facilitate the identification of molecular signatures that are associated with breast tumor cell phenotype. The appropriate use of these approaches has the potential to provide efficient biomarkers, and to improve our knowledge of tumor biology. This, in turn, will enable the development of targeted therapeutics aimed at ameliorating the lethal dissemination of breast cancer. In this review, we focus on the accumulating proteomic signatures of breast tumor progression, particularly those that correlate with the occurrence of distant metastases, and discuss some of the expected future developments in the field.
KW - 2D separation
KW - Biomarkers
KW - Breast cancer
KW - Laser-capture microdissection
KW - Molecular prognostics
KW - Oncoproteomics
KW - Tissue microarray
UR - http://www.scopus.com/inward/record.url?scp=45749147868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45749147868&partnerID=8YFLogxK
U2 - 10.1586/14789450.5.3.457
DO - 10.1586/14789450.5.3.457
M3 - Review article
C2 - 18532913
AN - SCOPUS:45749147868
VL - 5
SP - 457
EP - 467
JO - Expert Review of Proteomics
JF - Expert Review of Proteomics
SN - 1478-9450
IS - 3
ER -